Buradasınız

Anasayfa » Content

Demir Eksikliği Anemisinin Tedavisinde Oral Ferros Sülfat ve Ferrik Polimaltozun Etkinliğinin Karşılaştırılması

The Comparison of Ferrous Sulphate and Ferric Polymaltose Treatment Efficacy of Iron Deficiency Anemia

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Background: The effect of ferric polymaltose in therapy of iron deficiency anemia is disputatious. In a prospective, randomised study, a bivalent iron salt (ferrous sulphate) was compared with a trivalent ferric hydroxide complex (ferric polymaltose) to compare treatment efficiancy and side effects. Material and Methods: A total 60 females diagnosed as having iron deficiency anemia with clinical and laboratory findings are divided into two groups. Ferrous sulphate (160 mg /daily) was given to one group and ferric polymaltose (1 60 mg/daily) was given to the other for six weeks. Hemoglobin, mean corpuscular volume, transferrin saturation and serum ferritin level were studied in both groups before and after therapy. Findings: Hemoglobin was increased in the group with ferrous sulphate therapy, but no statistical difference was found on mean corpuscular volume, transferrin saturation and serum ferritin level between two groups. Conclusion: Ferrous sulphate threapy elevated the hemoglobin level in a shorter time than ferric polymaltose therapy.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Demir eksikliği anemisi tedavisinde ferrik polimaltozun etkinliği tartışmalıdır. İki değerlikli demir tuzu (ferros sülfat) ile üç değerlikli demir hidroksi karbonhidrat kompleksinin (ferrik polimaltoz) prospektif rand omize klinik bir çalışmada tedavi etkinliği ve yan etkilerinin karşılaştırılması amaçlandı. Gereç ve Yöntem: Demir eksikliği anemi tanısı konulan 60 kadın olgu iki gruba ayrıldı. Altı hafta süreyle bir gruba 160 mg/gün ferros sülfat, diğer gruba ise 160 mg /gün ferrik polimaltoz verildi. Tedavi öncesi ve sonrası hemoglobin, ortalama eritrosit hacmi, transferrin saturasyonu ve serum ferritin düzeyleri çalışıldı. Bulgular: Tedavi sonrası hemoglobin, ferros sülfat kullanan grupta ferrik polimaltoz kullanan grub a göre anlamlı olarak daha yüksek olmasına karşın iki grup arasında ortalama eritrosit hacmi, transferrin saturasyonu ve serum ferritin düzeylerinde farklılık tespit edilemedi. Sonuç: Ferros sülfat tedavisi, hemoglobini daha kısa sürede yükseltmiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-demir-eksikligi-anemisinin-tedavisinde-oral-ferros-sulfat-ferrik-polimaltozun-etkinliginin-karsilastirilmasi.pdf
  • 4
213-216
  • Turkish

REFERENCES

References: 

1. DeMaeyer E, Adiels-Tegman M. The prevalence of anaemia in the world. World Health Stat Q 1985; 38: 302-6.
2. Hoffrbrand AV, Pettit JE. Iron deficiency and other hypochromic a naemias. In: Essential Haematology. 3 rd ed. Oxford, Blackwell Scientific. 1993: 36 -52.
3. Hallberg L. Bioavailability of dietary iron in man. Annu Rev Nutr 1981; 1: 123 -47.
4. Hallberg L, Rossander-Hulten L. Iron requirements in menstruating women. Am J Clin Nutr 1991; 54: 1047-58.
5. Frewin R, Henson A, Provan D. Iron deficiency anaemia. BMJ 1997; 314: 360 -3.
6. Provan D. Mechanisms and management of iron deficiency anaemia. British J
Haematol 1999; 105: 19-26.
7. Lee GR. Iron deficiency and iron -deficiciency anemia. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, editors. Wintrobe's Clinical Hematology. 10 th ed. Williams & Wilkins, 1999: 979-1010.
8.
Çeti
n M, Eser B, Güven M, Ünal A, Altınbaş M. Oral demir tedavisinde ferro sülfat ve ferrik polimaltoz etkinliğinin karşılaştırılması. THOD 1999; 9: 96 -100.
9. Jacobs P, Wormald LA, Gregory MC. Absorption of iron polymaltose and ferrous sulphate in rats and humans. A comparative study. S Afr Med J 1979; 55: 1065 -72.
10. Harvey RS, Reffitt DM, Doig LA, Meenan J , Ellis RD, Thompson RP, Powell JJ. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron.
Aliment Pharmacol Ther 1998; 12: 845 -8.
11. Sas G, Nemesanszky E, Brauer H, Scheffer K. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia. Arzneimittel forschung 1984; 34: 1575-9.
12. Jacobs P, Johnson G, Wood L. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J Med 1984; 15: 367 -77.
13. Forth W, Schafer SG. Abs orption of di- and trivalent iron. Experimental evidence. Arzneimittel forschung 1987; 37: 96 -100.
14. Schafer S, Forth W. On the absorption of divalent and trivalent iron in living rats. Arzneimittel forschung 1984; 34: 1570 -4.
15. Geisser P, Muller A. Pharmacoki netics of iron salts and ferric hydroxide -carbohydrate complexes. Arzneimittel forschung 1987; 37: 100 -4.
16. Geisser P. In vitro studies on interactions of iron salts and complexes with food -stuffs and medicaments. Arzneimittel forschung 1990; 40: 754 -60.
17. Casparis D, Del Carlo P, Branconi F, Grossi A. Effectiveness and tolerability of oral liquid ferrous gluconate in iron -deficiency anemia in pregnancy and in the immediate post-partum period: comparison with other liquid or solid formulations containing bivale nt or trivalent iron. Minerva Ginecol 1996; 48: 511 -
8.
18. Liguori L. Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1000 patients. Int J Clin Pharmacol
Ther Toxicol 1993; 31:103-23.
19. Kopcke W, Sauerland MC. Meta -analysis of efficacy and tolerability data on iron proteinsuccinylate in patients with iron deficiency anemia of different severity.
Arzneimittel forschung 1995; 45:1211 -6.

Thank you for copying data from http://www.arastirmax.com